Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?

Por Kouroupi, E, Kiladjian, J-J, Dosquet, C, Menot, M-L, Bonnin, N, Ades, L, Vainchenker, W, Chomienne, C, Cassinat, B
Publicado em 2012

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Por Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F, Jones, M M, Sun, K, McQuitty, M, Stalbovskaya, V, Gopalakrishna, P, Barbui, T
Publicado no Leukemia (2016)

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Por Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P
Publicado no Leukemia (2017)

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium

Por Tefferi, A, Abdel-Wahab, O, Cervantes, F, Crispino, J D, Finazzi, G, Girodon, F, Gisslinger, H, Gotlib, J, Kiladjian, J-J, Levine, R L, Licht, J D, Mullally, A, Odenike, O, Pardanani, A, Silver, R T, Solary, E, Mughal, T
Publicado em 2011

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

Por Gisslinger, Heinz, Gotic, Mirjana, Holowiecki, Jerzy, Penka, Miroslav, Thiele, Juergen, Kvasnicka, Hans-Michael, Kralovics, Robert, Petrides, Petro E., Gastl, G., Gisslinger, B., Muellauer, L., Schlögl, E., Indrak, K., Pytlik, R., Briere, J., Kiladjian, J.J., Beykirch, M., Gaede, B., Griesshammer, M., Herbrik-Zipp, M., Hurtz, H.J., Jacobs, G., Jäcki, S.H., Keilholz, U., Mezger, J., Schlag, P., Schriever, F., Masszi, T., Sacchi, S., Griniptì, R., Tavoriene, I., Dmoszynska, A., Hellman, A., Jedrzejczak, W.W., Robak, T., Skotnicki, A., Goh, Y.T., Cernelc, P.
Publicado em 2013

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neopla...

Por Jovanovic, J V, Ivey, A, Vannucchi, A M, Lippert, E, Oppliger Leibundgut, E, Cassinat, B, Pallisgaard, N, Maroc, N, Hermouet, S, Nickless, G, Guglielmelli, P, van der Reijden, B A, Jansen, J H, Alpermann, T, Schnittger, S, Bench, A, Tobal, K, Wilkins, B, Cuthill, K, McLornan, D, Yeoman, K, Akiki, S, Bryon, J, Jeffries, S, Jones, A, Percy, M J, Schwemmers, S, Gruender, A, Kelley, T W, Reading, S, Pancrazzi, A, McMullin, M F, Pahl, H L, Cross, N C P, Harrison, C N, Prchal, J T, Chomienne, C, Kiladjian, J J, Barbui, T, Grimwade, D
Publicado em 2013